GordonMD Global Investments

Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease. It is a spin-off from Ultragenyx Pharmaceutical.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule therapies that facilitate the targeted delivery of therapeutic radioisotopes to solid tumors. By focusing on these advanced treatment options, Radionetics Oncology seeks to enhance the effectiveness of cancer therapies and improve patient outcomes in oncology care.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Flare Therapeutics is a biotechnology company that develops small-molecule medicines by targeting transcription factors. It focuses on identifying switch sites—druggable regions that regulate transcription factor activity—to address disease-causing mutations. Leveraging insights into transcription factor biology, Flare aims to translate this understanding into precision medicines, building an early pipeline that is initially focused on precision oncology with potential expansions into neurology, rare genetic disorders, immunology, and inflammation. The company combines a drug-discovery platform with a biology-led approach to discover therapies that alter the trajectory of diseases driven by transcription factor dysregulation.

Founded in 2017, Spotlight Therapeutics develops innovative therapeutics based on its targeted active gene editing platform. The company focuses on creating biologics tailored to specific cell populations, with initial programs in immuno-oncology, ophthalmology, and hematology.

SalioGen Therapeutics develops curative therapies for inherited disorders using its Exact DNA Integration Technology (EDIT) platform. EDIT employs proprietary mammal-derived enzymes called Saliogase, enabling non-viral delivery of genes of any size and offering significant manufacturing advantages.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.